| Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma P Strati, S Ahmed, F Furqan, LE Fayad, HJ Lee, SP Iyer, R Nair, ... Blood, The Journal of the American Society of Hematology 137 (23), 3272-3276, 2021 | 143 | 2021 |
| Prevalence and mortality of COVID-19 patients with gastrointestinal symptoms: a systematic review and meta-analysis R Tariq, S Saha, F Furqan, L Hassett, D Pardi, S Khanna Mayo Clinic Proceedings 95 (8), 1632-1648, 2020 | 143 | 2020 |
| Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel). S Ahmed, F Furqan, P Strati, J Westin, L Fayad, FB Hagemeister, HJ Lee, ... Journal of Clinical Oncology 38 (15_suppl), 8057-8057, 2020 | 20 | 2020 |
| Multispecific CAR T cells deprive lymphomas of escape via antigen loss F Furqan, NN Shah Annual Review of Medicine 74 (1), 279-291, 2023 | 15 | 2023 |
| Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data F Furqan, M Hamadani Therapeutic Advances in Hematology 13, 20406207221087511, 2022 | 14 | 2022 |
| Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel). P Strati, F Furqan, J Westin, L Fayad, S Ahmed, HJ Lee, SP Iyer, R Nair, ... Journal of Clinical Oncology 38 (15_suppl), 8011-8011, 2020 | 14 | 2020 |
| Bispecific CAR T-cells for B-cell malignancies F Furqan, NN Shah Expert Opinion on Biological Therapy 22 (8), 1005-1015, 2022 | 12 | 2022 |
| Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax ML Marques-Piubelli, EJ Schlette, JD Khoury, F Furqan, F Vega, ... Leukemia & lymphoma 62 (5), 1129-1135, 2021 | 8 | 2021 |
| Efficacy and safety of half‐dose desmopressin for bleeding prophylaxis in bleeding disorder patients undergoing predominantly low to moderate risk invasive procedures F Furqan, R Sham, P Kouides American Journal of Hematology 95 (10), E285-E287, 2020 | 8 | 2020 |
| Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma F Furqan, KW Ahn, Y Chen, M Kaur, SA Abutalib, N Ahmed, S Ahmed, ... British journal of haematology 200 (1), 54-63, 2023 | 7 | 2023 |
| Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis: 207 R Tariq, S Saha, A Wahab, F Furqan, E Olson, D Pardi, S Khanna Official journal of the American College of Gastroenterology| ACG 113, S121, 2018 | 5 | 2018 |
| A multicenter experience: duration of mandatory CRS and ICANS monitoring for myeloma and lymphoma CAR-T recipients W Wesson, D Dima, J Davis, A Rashid, F Furqan, MSI Saif, E Logan, ... Transplantation and Cellular Therapy 30 (2), S207-S208, 2024 | 3 | 2024 |
| Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort JT Bowers, J Anna, SM Bair, K Annunzio, N Epperla, JJ Pullukkara, ... Blood Advances 7 (21), 6630-6638, 2023 | 3 | 2023 |
| Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy F Furqan, M Maring, A Szabo, TS Fenske, M Hamadani, NN Shah Blood Advances 7 (11), 2463-2467, 2023 | 3 | 2023 |
| In reply—Lack of Marked Association Between Gastrointestinal Symptoms and COVID-19 Mortality: An Updated Meta-analysis Based on Adjusted Effect Estimates R Tariq, S Saha, F Furqan, D Pardi, S Khanna Mayo Clinic Proceedings 96 (6), 1680-1681, 2021 | 3 | 2021 |
| Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement F Furqan, G Watson, F Samaniego, LE Fayad, R Kanagal-Shamanna, ... Leukemia & lymphoma 61 (12), 2980-2984, 2020 | 3 | 2020 |
| Timing of Toxicities and Non-relapse Mortality Following CAR T Therapy in Myeloma W Wesson, D Dima, N Suleman, MSI Saif, C Tabak, E Logan, JA Davis, ... Transplantation and Cellular Therapy, 2024 | 2 | 2024 |
| Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers E Ayers, V Zelikson, A Gurumurthi, Y Sawalha, K Annunzio, A Saha, ... Blood 142, 312, 2023 | 2 | 2023 |
| Adaptive manufacturing of LV20. 19 CAR T-cells for relapsed, refractory mantle cell lymphoma NN Shah, F Furqan, A Szabo, T Kearl, A Zamora, J Neumann, PN Hari, ... Blood 142, 1024, 2023 | 2 | 2023 |
| MRD status by Clonoseq® is a poor predictor of long-term outcomes after bispecific LV20. 19 CAR T-cell therapy for relapsed, refractory B-cell NHL F Furqan, TS Fenske, WL Longo, B Johnson, M Hamadani, NN Shah Blood 140 (Supplement 1), 6407-6408, 2022 | 2 | 2022 |
